![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CanSino Biologics and Precision NanoSystems to Codevelop COVID-19 Vaccine
CanSino Biologics and Precision NanoSystems to Codevelop COVID-19 Vaccine
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
China’s CanSino Biologics has teamed up with Vancouver, Canada-based Precision NanoSystems (PNI) to codevelop a COVID-19 vaccine using messenger RNA lipid nanoparticles.
PNI will develop the candidate vaccine, and CanSino will take the lead for clinical testing and regulatory approval.
If successful, CanSino plans to commercialize the mRNA vaccine product in Asia, excluding Japan, while PNI will retain rights for the rest of the world.
Upcoming Events
-
18Jul
-
21Oct